TG Therapeutics: An Immunology Powerhouse | RSS News Feed

TG Therapeutics: An Immunology Powerhouse - Latest News

RSS Feed for this news: TG Therapeutics: An Immunology Powerhouse

TG Therapeutics: An Immunology Powerhouse

Finances: Enough liquid assets to support the company until at least Q1 2019, with similar cash burns expected in the near future. Market potential by indication: $1.7 billion (relapsed/refractory CLL), $2.1 billion (relapsed/refractory NHL), and $23.4 ... read more

Coronado Biosciences Forms New Subsidiary, Checkpoint Therapeutics, to Develop Novel Immuno-Oncology Antibodies

Checkpoint and TG Therapeutics ... Checkpoint Therapeutics, Inc., to develop a portfolio of fully human immuno-oncology targeted antibodies generated in the laboratory of Dr. Wayne Marasco, MD, PhD, a Professor in the Department of Cancer Immunology ... read more

Flare-responsive hydrogel developed to treat arthritis

"Although new therapeutics have been developed ... The newly created flare-responsive hydrogel is made from triglycerol monostearate (TG-18), a compound from the Food and Drug Administration's list of "generally recognized as safe" compounds. read more

Looking for another news?


Confluence’s $100 million acquisition is a win for St. Louis’ biotech sector

Yesterday, BioGenerator’s first co-working lab tenant, Confluence Life Sciences, got acquired by Aclaris Therapeutics ... by the team of St. Louis scientists’ achievements in immunology, as a whole. Aclaris senior VP Dick told me that initial ... read more

TG Therapeutics, Inc. Announces Clinical and Preclinical Data Presentations at the 23rd Congress of the European Hematology Association

NEW YORK, June 15, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the presentation of an integrated analysis of long term safety data of umbralisib (TGR-1202), the Company’s PI3K delta inhibitor, either dosed as a single ... read more

Manhattan Pharmaceuticals Names Mary C. Spellman, M.D. as Head of Dermatology and Drug Development

December 27, 2007 09:59 ET | Source: TG Therapeutics ... aesthetic and medical, dermatologic therapeutics. Prior to Revance, she was Senior Director, Medical Research, Immunology at Biogen Idec, Inc. where she led all phases of global immunology clinical ... read more

TG Therapeutics : Provides Business Update and Reports First Quarter 2018 Financial Results

NEW YORK - TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the first quarter ended March 31, 2018 and recent company developments. Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, stated ... read more


FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us